Cabaletta Bio, INC Form 4 insider transactions

Anup Marda, CFO of Cabaletta Bio, receives repriced stock options with a new exercise price of $1.92 per share, effective May 19, 2025.

Director Simon Mark reports repricing of stock options at Cabaletta Bio, effective May 19, 2025.

Gwendolyn Binder, President of Science & Technology at Cabaletta Bio, Inc., received repriced stock options effective May 19, 2025, as approved by the board of directors.

Arun Das, Chief Business Officer of Cabaletta Bio, receives repriced stock options effective May 19, 2025, under the company's stock option and incentive plans.

Catherine Bollard, a director at Cabaletta Bio, reported a repricing of stock options effective May 19, 2025, according to a Form 4 filing with the SEC.

David J. Chang, Chief Medical Officer of Cabaletta Bio, Inc., receives repriced stock options effective May 19, 2025.

Gwendolyn Binder, President of Science & Technology at Cabaletta Bio, Inc., reports the acquisition of stock options.

Anup Marda, CFO of Cabaletta Bio, Inc., was granted stock options for 145,000 shares on March 3, 2025.

Michael Gerard, General Counsel of Cabaletta Bio, Inc., reports the acquisition of stock options.

Arun Das, Chief Business Officer of Cabaletta Bio, Inc., was granted stock options for 115,000 shares on March 3, 2025.

David J. Chang, Chief Medical Officer of Cabaletta Bio, Inc., reports the acquisition of stock options.

Steven Nichtberger, CEO of Cabaletta Bio, Inc., reports the acquisition of 450,000 stock options at an exercise price of $1.67 on March 3, 2025.

Director Catherine Bollard acquired 22,000 stock options in Cabaletta Bio, Inc. on June 3, 2024.

Director Simon Mark reports the acquisition of stock options in Cabaletta Bio, Inc.

Director Richard C Henriques Jr. acquired 22,000 stock options in Cabaletta Bio, Inc. on June 3, 2024, according to a Form 4 filing.

Director Scott C. Brun reports the acquisition of stock options for 22,000 shares of Cabaletta Bio, Inc. at an exercise price of $10.01.

Director Shawn Tomasello reports the acquisition of stock options in Cabaletta Bio, Inc.

Michael Gerard, General Counsel of Cabaletta Bio, Inc., reports the acquisition of stock options for 100,000 shares on March 1, 2024.

David J. Chang, Chief Medical Officer of Cabaletta Bio, Inc., reports the acquisition of stock options.

Steven Nichtberger, CEO of Cabaletta Bio, Inc., reports the acquisition of 353,000 stock options on March 1, 2024.

Anup Marda, CFO of Cabaletta Bio, Inc., was granted stock options for 130,000 shares on March 1, 2024, according to a Form 4 filing with the SEC.

Arun Das, Chief Business Officer of Cabaletta Bio, Inc., reports the acquisition of stock options for 100,000 shares on March 1, 2024.

Gwendolyn Binder, President of Science & Technology at Cabaletta Bio, Inc., was granted stock options for 130,000 shares on March 1, 2024, according to a Form 4 filing.